Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.59 USD
Change Today -0.77 / -2.24%
Volume 418.2K
MYGN On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/1/14 - $42.50
52 Week Low
11/17/14 - $31.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYRIAD GENETICS INC (MYGN)

myriad genetics inc (MYGN) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYGN) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. The company operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes; diagnose diseases, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

1,649 Employees
Last Reported Date: 08/13/14
Founded in 1991

myriad genetics inc (MYGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $997.0K
President of Myriad Genetic Laboratories
Total Annual Compensation: $568.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $734.0K
Chief Scientific Officer
Total Annual Compensation: $733.6K
Compensation as of Fiscal Year 2014.

myriad genetics inc (MYGN) Key Developments

Myriad Genetics, AstraZeneca to Expand Collaboration on Lynparza Testing for Pancreatic Cancer

Myriad Genetics has expanded diagnostic collaboration with AstraZeneca under which its BRACAnalysis CDx test will be used to identify which patients with metastatic pancreatic cancer may respond to treatment with AstraZeneca's Lynparza. The BRACAnalysis CDx test was approved in December 2014 by the U.S. Food and Drug Administration to identify ovarian cancer patients with germline mutations in BRCA1/2 who may be appropriate for treatment with Lynparza.

Myriad Genetics Inc. Announces Prolaris Test Biopsy Results from EMPATHY-P Study at European Association of Urology Annual Meeting

Myriad Genetics Inc. announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods (D'Amico/AUA risk stratification), which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology. Specifically, EMPATHY-P demonstrated that the Prolaris test score found 22% of the European patients had less aggressive prostate cancer and 20% had more aggressive prostate cancer compared to standard clinical pathology measurements. Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy.

Myriad Genetics Seeks Acquisitions

Mark Capone, President, Chief Executive Officer & Director of Myriad Genetics Inc. (NasdaqGS:MYGN) said, "I think as we reflect on that, I would love to find other opportunities like Crescendo that are generating this level of revenue that have line of sight to being accretive in the not too distant future in a very large market that's $1.5 billion market that can be served by 40 sales people. I would love to have other acquisition opportunities in that category. Unfortunately, there are not that many quality opportunities out there in this space and that's why you haven't seen us be more acquisitive, but certainly, we would take that opportunity anytime we could get it to find an asset like that."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $33.59 USD -0.77

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.85 USD +0.07
Alliance HealthCare Services Inc $23.09 USD -0.29
Bio-Reference Laboratories Inc $35.23 USD +0.22
Genomic Health Inc $30.59 USD -0.29
RadNet Inc $8.95 USD -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation MYGN Industry Range
Price/Earnings 23.8x
Price/Sales 3.4x
Price/Book 3.5x
Price/Cash Flow 22.1x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at